European Parliament 21 January 2002, WRITTEN QUESTION P-0093/02 by Gabriele Stauner (PPE-DE) to the Commission. Irregularities involving ESF funds in North Rhine-Westphalia.

The number of licence approvals in a country, whether falling or rising, bears no relation to the number of clinical trials conducted in that country and there is no evidence that companies are switched from the US to conduct trials in the EU because of a laxer clinical trial environment.